6 research outputs found
Additional file 2: of Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study
SF-36 assessments over time. In this additional file, evolutions in SF-36 assessments are described through figures in the 1-year cohort (47 AKI-RRT (A) and 94 non-AKI-RRT patients (B)) and in the 4-year cohort (28 AKI-RRT (C) patients and 28 non-AKI-RRT patients (D)). Percentages of patients with some or severe problems in the different domains of the SF-36 are given over the different time points: baseline, 3Â months and 1Â year (1-year cohort) and baseline, 3Â months, 1Â year and 4Â years (4-year cohort). (PDF 126 kb
Neurological failure in ICU patients with hematological malignancies: A prospective cohort study
<div><p>Background</p><p>Epidemiological studies of neurological complications in patients with hematological malignancies are scant. The objective of the study was to identify determinants of survival in patients with hematological malignancy and neurological failure.</p><p>Methods</p><p>Post hoc analysis of a prospective study of adults with hematological malignancies admitted for any reason to one of 17 university or university-affiliated participating ICUs in France and Belgium (2010–2012). The primary outcome was vital status at hospital discharge.</p><p>Results</p><p>Of the 1011 patients enrolled initially, 226 (22.4%) had neurological failure. Presenting manifestations were dominated by drowsiness or stupor (65%), coma (32%), weakness (26%), and seizures (19%). Neuroimaging, lumbar puncture, and electroencephalography were performed in 113 (50%), 73 (32%), and 63 (28%) patients, respectively. A neurosurgical biopsy was done in 1 patient. Hospital mortality was 50%. By multivariate analysis, factors independently associated with higher hospital mortality were poor performance status (odds ratio [OR], 3.99; 95%CI, 1.82–9.39; <i>P</i> = 0.0009), non-Hodgkin’s lymphoma (OR, 2.60; 95%CI, 1.35–5.15; <i>P</i> = 0.005), shock (OR, 1.95; 95%CI, 1.04–3.72; <i>P</i> = 0.04), and respiratory failure (OR, 2.18; 95%CI, 1.14–4.25; <i>P</i> = 0.02); and factors independently associated with lower hospital mortality were GCS score on day 1 (OR, 0.88/point; 95%CI, 0.81–0.95; <i>P</i> = 0.0009) and autologous stem cell transplantation (OR, 0.25; 95%CI, 0.07–0.75; <i>P</i> = 0.02).</p><p>Conclusions</p><p>In ICU patients with hematological malignancies, neurological failure is common and often fatal. Independent predictors of higher hospital mortality were type of underlying hematological malignancy, poor performance status, hemodynamic and respiratory failures, and severity of consciousness impairment. Knowledge of these risk factors might help to optimize management strategies.</p></div
Patient characteristics and predictors of hospital mortality identified by logistic regression.
<p>Patient characteristics and predictors of hospital mortality identified by logistic regression.</p
Spectrum of acute organ failures on the first ICU day according to type of hematological malignancy in 1011 patients requiring ICU admission.
<p>Spectrum of acute organ failures on the first ICU day according to type of hematological malignancy in 1011 patients requiring ICU admission.</p
Patient flow chart.
<p><sup>a</sup> defined as bedridden or completely disabled. <sup>b</sup> number of organ failures at ICU admission defined according to the SOFA score. <sup>c</sup> investigations for a cause. First value indicates total number, and second value indicates when the exploration was deemed directly contributive to the final diagnosis.</p
MOESM1 of Management of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SF2H), and the French Infectious Diseases Society (SPILF)
Additional file 1. Non exhaustive list of non invasive test that may be considered for diagnostic of acute respiratory failure